Janux Therapeutics stockholders elect three Class I directors, ratify auditor at 2022 annual meeting

Janux Therapeutics, Inc.

David Campbell, Ron Barrett, and Stefan Heller elected as Class I directors with 33.9M, 34.7M, and 33.9M votes for, respectively.
Ernst & Young LLP ratified as independent auditor for FY2022 with 37.85M votes for, 3 against, 244 abstentions.
Broker non-votes of 2,998,529 on all director elections; none on auditor ratification.
Total outstanding shares as of record date April 18, 2022: 41,629,367.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.